USC researchers link genetic marker to rectal cancer treatment
Keck School of Medicine team is first to find link between EGF61 variant and cetuximab-based therapy
2011-07-07
(Press-News.org) A team of researchers led by Keck School of Medicine of the University of Southern California (USC) oncologist Heinz-Josef Lenz, M.D., has identified a genetic marker that may predict which patients with rectal cancer can be cured by certain chemotherapies when combined with surgery. The discovery, scheduled for publication in the August 1 edition of Clinical Cancer Research, brings doctors closer to customizing cancer treatment to individual patients.
Lenz, professor of medicine and preventive medicine in the division of medical oncology at the Keck School and the study's principal investigator, analyzed the DNA of European patients with locally advanced rectal cancer who were treated with cetuximab (marketed as Erbitux) prior to surgery.
"Cetuximab is usually used for metastatic colon cancer, for which it is effective. We're asking if it could be effective for locally advanced rectal cancer," said Lenz, associate director of the Gastrointestinal Oncology Program at the USC Norris Comprehensive Cancer Center and Hospital.
Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death among men and women in the United States, according to the American Cancer Society. The disease develops in the colon or rectum and, if detected in its early stages, usually can be completely removed by surgery. When it is locally advanced, however, the tumor cannot be easily removed and doctors prescribe chemotherapy and radiation to make it more manageable before attempting surgical removal.
The retrospective analysis, first published online on June 14, found that 45 percent of patients with a particular genetic combination (EGF 61 G/G) emerged disease-free when treated with cetuximab before surgery, compared to 21 percent and 2 percent of patient groups who did not have the same genotype. This is the first study to suggest that the genetic variation — detectable by blood test — can be used to predict whether a patient with locally advanced rectal cancer will respond to cetuximab before surgery.
Cetuximab is a drug that is typically used to treat head and neck cancer and colorectal cancer that has spread to other parts of the body. It blocks epidermal growth factor receptors (EGFR) from binding with epidermal growth factor (EGF) proteins found in the body, which have been linked to increased risk for cancer. For tumors that are difficult to cut out but have not yet spread to other parts of the body, the standard treatment is a combination of capecitabine (Xeloda), fluorouracil (5-FU) and radiation. The patients in the study received intravenous doses of cetuximab in addition to standard care.
INFORMATION: Additional data is required to validate the results, Lenz said. His lab is participating in another trial looking at a larger sample size in the United States.
The study was performed in the Sharon A. Carpenter Laboratory at the USC Norris Comprehensive Cancer Center and Hospital and funded by the National Institutes of Health, Dhont Family Foundation, Deutsche Forschungsgemeinschfat (DFG), Cologne Fortune and San Pedro Peninsula Cancer Guild. It is the second study published in Clinical Cancer Research that uses the same data set; the first measured gene expression levels of proteins involved in tumor growth. Co-authors include Siwen Hu-Lieskovan, Wu Zhang, Dongyun Yang, Alexander Pohl and Melissa Labonte, among others.
END
ELSE PRESS RELEASES FROM THIS DATE:
2011-07-07
Archaea are among the oldest known life-forms, but they are not well understood. It was only in the 1970s that these single-celled microorganisms were designated as a domain of life distinct from bacteria and multicellular organisms called eukaryotes.
Robert Gunsalus, a UCLA professor of microbiology, immunology and molecular genetics, developed an interest in Archaea because of their ability to thrive in harsh environments. Now, using state-of-the-art imaging equipment at the California NanoSystems Institute (CNSI) at UCLA, he has shown for the first time that a type ...
2011-07-07
EUGENE, Ore. -- Emerging from the heads of most cud-chewing mammals, headgear inspire an almost mystical and certainly majestic aura. But, scientists say, we know shockingly little about them.
In a paper appearing online ahead of regular publication in the Proceedings of the Royal Society B, a London-based international journal dedicated to biology, a three-member scientific team spells out what is known -- and not known -- about antlers, horns, pronghorns and ossicones.
For antlers, think deer, moose and elk. Horns are worn by cattle, sheep and goats; ossicones by ...
2011-07-07
Increasing a specific protein in areas of the pancreas that produce insulin blocks the immune attack that causes type 1 diabetes, researchers reported in the August issue of the Journal of Clinical Investigation, published early online.
The discovery could lead to a drug that prevents the progression of type 1 diabetes in people newly diagnosed who are in the "honeymoon" phase of the disease, when the immune system has not yet destroyed all of the insulin-producing beta cells in the pancreas.
The finding could also lead to new drugs for overcoming organ rejection in ...
2011-07-07
July 5, 2011– Anxiety, stress and depression during pregnancy may lead to a greater risk of asthma for your child, according to researchers at Columbia University's Mailman School of Public Health. Study results are published in the July issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).
"Approximately 70% of mothers who said they experienced high levels of anxiety or depression while they were pregnant reported their child had wheezed before age 5," said Marilyn Reyes, senior research ...
2011-07-07
Researchers at the Johns Hopkins University School of Medicine have developed a technique that delivers gene therapy into human brain cancer cells using nanoparticles that can be freeze-dried and stored for up to three months prior to use. The shelf-stable particles may obviate the need for virus-mediated gene therapy, which has been associated with safety concerns. The report appears in the August issue of Biomaterials.
"Most nonviral gene therapy methods have very low efficacy," says Jordan Green, Ph.D., an assistant professor of biomedical engineering at Johns Hopkins. ...
2011-07-07
A significant discovery by University of Adelaide researchers shows that the loss of a twin during early pregnancy explains the increased risk of birth defects in multiple IVF pregnancies.
The annual meeting of the European Society of Human Reproduction and Embryology in Stockholm today will hear Associate Professor Michael Davies explain how the "vanishing twin" phenomenon is linked to a nearly two-fold increased risk of congenital malformation in the surviving baby, and a threefold increase in multiple birth defects.
The phenomenon occurs when there are fewer babies ...
2011-07-07
ST. PAUL, Minn. – New research finds breastfeeding doesn't appear to protect against multiple sclerosis (MS) relapses, despite previous studies suggesting there may be a protective role. The research is published in the July 6, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology (AAN).
"Breastfeeding should not be encouraged by doctors to protect against MS relapses, especially among women with MS who have high disease activity and high risk of postpartum relapses," said study author Emilio Portaccio, MD, of the University of Florence ...
2011-07-07
If Canada's smoking rates were cut by half to an average national rate of 11% within five years, it would result in 35,900 fewer cases of lung cancer by 2030 and save $656 million in treatment costs, according to analysis using a new web-enabled platform developed for the Canadian Partnership Against Cancer and presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).
"The Cancer Risk Management simulation model developed for the Canadian Partnership Against Cancer simulates the demographic ...
2011-07-07
Women, older people and minorities are enrolled less frequently in lung cancer drug trials and the numbers do not reflect the prevalence of lung cancer in these populations, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).
"Our results suggest that the trial population used for approval of drugs do not represent well the U.S. population who may receive the marketed agent," said principal investigator Dr. Shakun Malik, a medical officer at the U.S. Food ...
2011-07-07
New developments such as stereotactic ablative radiotherapy and improvements in surgical care in early-stage lung cancer have led to large survival gains for elderly Dutch patients, according to a population-based study presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).
The median survival for Dutch non-small cell lung cancer (NSCLC) patients increased by nearly 8 months between 2003 and 2009, following the advent of stereotactic ablative radiotherapy.
"In fit patients, surgery ...
LAST 30 PRESS RELEASES:
[Press-News.org] USC researchers link genetic marker to rectal cancer treatment
Keck School of Medicine team is first to find link between EGF61 variant and cetuximab-based therapy
